CVAC

EQS-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

Retrieved on: 
Tuesday, August 22, 2023
Vaccine, BioNTech, GMP, Operating cost, GSK, Intellectual property, Workforce, Omicron, Palatine Higher Regional Court, Vaccination, COVID-19, Infection, Clinical trial, CureVac, Cancer, Pfizer–BioNTech COVID-19 vaccine, CMO, Part, Astrocytoma, Messenger, Sale, Research and development, Development, Radiation, HIV disease progression rates, Patent, Patient, Hearing, Sąd rejonowy, Epitope, Research, CVAC, Safety, Virus, Pfizer, Cryptocurrency, Fine chemical, Pharmaceutical industry, Glioblastoma

“During the first six months of 2023, we continued building on the momentum from the strong start to the year.

Key Points: 
  • “During the first six months of 2023, we continued building on the momentum from the strong start to the year.
  • “Our unwavering commitment to innovation has enabled us to further expand our intellectual property portfolio, strengthening our mRNA technology ownership.
  • All jointly tested candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses.
  • The first six months of 2022 were positively impacted by €21.3 million related to the reversal of an outstanding CRO provision.

EQS-News: CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

Retrieved on: 
Tuesday, August 1, 2023
Vaccine, GSK, Vaccination, SARS-CoV-2, COVID-19, CureVac, Messenger, Immunodeficiency, CVAC, Safety, Pharmaceutical industry

TÜBINGEN, Germany / BOSTON, USA – August 1, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in the Phase 2 study of monovalent and bivalent modified mRNA COVID-19 vaccine candidates, developed in collaboration with GSK.

Key Points: 
  • TÜBINGEN, Germany / BOSTON, USA – August 1, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in the Phase 2 study of monovalent and bivalent modified mRNA COVID-19 vaccine candidates, developed in collaboration with GSK.
  • A first data read-out of the study is expected early in the first half of 2024.
  • As previously reported, in CureVac and GSK’s ongoing Phase 1 trial of CV0501, a monovalent, modified mRNA COVID-19 vaccine candidate encoding the spike protein of the omicron BA.1 variant, preliminary data showed a favorable tolerability profile.
  • Preliminary immunogenicity data indicated relevant ratios of post-boost to pre-boost neutralizing antibody titers beginning at the lowest tested dose.

Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology

Retrieved on: 
Friday, July 21, 2023
Research, Finance, Genetics, Banking, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Myopathy, PNAS, Central nervous system, Biomedical Research, Novartis Institute for Tropical Diseases, Therapy, Executive director, University, NIBR, Investment, The W. Alton Jones Cell Science Center, Sofia University, Deafness, Infection, CureVac, Nature Genetics, Cancer, Howard Hughes Medical Institute, Boston, Multimedia, RNA, Doctor of Philosophy, CNS, Disorder, Messenger, Harvard Medical School, Human genetics, RTÉ Executive Board, Publication, Partner, Patient, Master of Science, The New England Journal of Medicine, RTW, Spectrum, Cardiomyopathy, Hospital, CVAC, Arrhythmia, Gene, III, Disease, Vaccine, Pharmaceutical industry, Achillea millefolium

Yarrow Biotechnology, Inc. (“Yarrow”), an RTW Investments, LP (“RTW”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system (“CNS”), today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer.

Key Points: 
  • Yarrow Biotechnology, Inc. (“Yarrow”), an RTW Investments, LP (“RTW”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system (“CNS”), today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer.
  • Prior to serving as Chief Scientific Officer of CureVac, Dr. Splawski spent fifteen years at the Novartis Institutes for BioMedical Research (NIBR).
  • Dr. Splawski has a PhD in Human Genetics from the University of Utah and an MSc in Biotechnology from Sofia University.
  • Splawski is recognized as a leading figure in the development of complex human genetic tests, protein biologics, and RNA therapies, and we are excited to welcome him to Yarrow,” said Peter Fong, PhD, Chief Executive Officer of Yarrow Biotechnology and Partner and Chief Development Officer at RTW.

EQS-News: CureVac Announces Update to the Management Team

Retrieved on: 
Friday, July 14, 2023
Growth, CureVac, CVAC, Therapy, Research, Trust, Messenger, Supervisory board, Vaccine

During the search for a successor, CureVac’s Chief Development Officer, Dr. Myriam Mendila, will head the advancement of CureVac’s unique mRNA technology platform and its integration with the clinical development of novel mRNA vaccines and therapeutics.

Key Points: 
  • During the search for a successor, CureVac’s Chief Development Officer, Dr. Myriam Mendila, will head the advancement of CureVac’s unique mRNA technology platform and its integration with the clinical development of novel mRNA vaccines and therapeutics.
  • “We are extremely grateful for Igor’s many contributions to CureVac’s research strategy and his vital role in bringing the company’s differentiated mRNA technology to the next level,” said Jean Stéphenne, Chairman of the Supervisory Board of CureVac.
  • “I truly enjoyed working with our brilliant scientists, who have pioneered some of the most significant breakthroughs in mRNA technology and continue to advance this exciting field.
  • I would like to thank my CureVac colleagues for their trust and support.”

EQS-News: CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

Retrieved on: 
Thursday, July 13, 2023
Vaccine, BioNTech, Patent, Intellectual property, Omicron, Palatine Higher Regional Court, Federal Patent Court (Germany), COVID-19, CureVac, Pfizer–BioNTech COVID-19 vaccine, Messenger, Bird & Bird, Bird, Sąd rejonowy, CVAC

Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights

Key Points: 
  • Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights
    Three new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in Germany, increasing number of asserted intellectual property rights to eight
    Tenth patent added to CureVac’s counterclaim against Pfizer/BioNTech in the U.S., covering innovations in mRNA purification methods highly relevant to the manufacturing of Comirnaty®
    TÜBINGEN, Germany – July 13, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has strengthened its position in the ongoing patent litigations with Pfizer/BioNTech in Germany and the U.S. by expanding the scope of both cases by asserting new intellectual property rights.
  • Patent litigation in Germany, originally filed by CureVac regarding four of its intellectual property rights in June 2022, was strengthened by the addition of a fifth intellectual property right as announced in May 2023 .These five intellectual property rights have now been extended by three more recent intellectual property rights: DE202021004123U1 and DE202021004130U1, providing protection to COVID-19 variant adapted vaccines, including the Omicron and XBB1.5 variants and EP4023755, relating to split poly A tail mRNA vaccines.
  • A preliminary opinion issued in April 2023 by the German Federal Patent Court supports the validity of the CureVac patent.
  • In the U.S., Pfizer/BioNTech filed its case in late July 2022, asking for confirmation that Comirnaty® does not infringe three CureVac patents.

EQS-News: CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

Retrieved on: 
Tuesday, June 20, 2023
Vaccination, CureVac, Part, Messenger, Glioblastoma, Astrocytoma, Alveolar soft part sarcoma, HIV disease progression rates, Patient, Epitope, CVAC, Safety, Vaccine

CVGBM is based on CureVac’s proprietary second-generation mRNA backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demon­strated relevance in glioblastoma.

Key Points: 
  • CVGBM is based on CureVac’s proprietary second-generation mRNA backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demon­strated relevance in glioblastoma.
  • “We are excited to enter the execution phase of our cancer vaccine development strategy with a study that is designed to establish proof-of-principle for our advanced second-generation mRNA backbone in oncology,” said Dr. Myriam Mendila, Chief Development Officer of CureVac.
  • CVGBM is administered as a monotherapy after surgical resection and completion of radio­therapy with or without chemotherapy.
  • The study will consist of two parts, a dose-escalation part (Part A) and a dose-expansion part (Part B).

EQS-News: CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board

Retrieved on: 
Tuesday, June 20, 2023
MorphoSys, CureVac, Messenger, Committee, Retirement, Supervisory board, CFO, CVAC, KPMG, Annual general meeting, Management

TÜBINGEN, Germany / BOSTON, USA – June 20, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Michael Brosnan as an independent director to the company's Supervisory Board.

Key Points: 
  • TÜBINGEN, Germany / BOSTON, USA – June 20, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Michael Brosnan as an independent director to the company's Supervisory Board.
  • Mr. Brosnan replaces Hans Christoph Tanner, who has been a member of CureVac’s Supervisory Board since 2015.
  • “Michael is an excellent addition to the CureVac board.
  • His global financial and audit experience will help manage financial stability as we move towards late-stage clinical development and commercialization,” said Jean Stéphenne, Chairman of CureVac’s Supervisory Board.

EQS-News: CureVac Announces Voting Results of General Meeting

Retrieved on: 
Monday, June 19, 2023
Supervisory board, CVAC, Security (finance)

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • TÜBINGEN, Germany / BOSTON, USA – June 19, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general meeting.
  • The shareholders of the Company voted in favor of all proposals.
  • A table containing tabulations of the votes casted is expected to be released in the coming days.

EQS-News: CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update

Retrieved on: 
Thursday, June 1, 2023
Vaccine, BioNTech, Operating cost, Workforce, GSK, Intellectual property, Federal Patent Court (Germany), SARS-CoV-2, COVID-19, Infection, Clinical trial, CureVac, CMO, IP, Messenger, Sale, Glioblastoma, Trial of the century, Research and development, Development, Patent, Patient, Research, CVAC, Safety, Virus, Pfizer, Pharmaceutical industry, Cryptocurrency, Video game, Pfizer–BioNTech COVID-19 vaccine

The increase was mainly driven by €219.8 million in net proceeds raised in a follow-on offering during February 2023.

Key Points: 
  • The increase was mainly driven by €219.8 million in net proceeds raised in a follow-on offering during February 2023.
  • The first quarter of 2022 was positively impacted by €6.8 million related to the reversal of an outstanding CRO provision.
  • Net financial result for the first quarter of 2023, amounted to €3.0 million, or an increase of €2.9 million from €0.1 million for the same period in 2022.
  • Pre-tax loss was €57.4 million for the first quarter of 2023 compared to €15.2 million in the same period of 2022.

EQS-News: CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

Retrieved on: 
Friday, May 19, 2023
Vaccine, BioNTech, Intellectual property, SARS-CoV-2, Federal Patent Court (Germany), CureVac, Pfizer–BioNTech COVID-19 vaccine, Messenger, Sale, Patent, Bird, CVAC, Generic drug, Pharmaceutical industry

The transfer is expected to significantly accelerate progress of the litigation, allowing for a likely 2024 trial date.

Key Points: 
  • The transfer is expected to significantly accelerate progress of the litigation, allowing for a likely 2024 trial date.
  • These nine patents cover foundational and highly relevant separate innovations in mRNA vaccine design, formulation and manufacturing specific to SARS-CoV-2 vaccines.
  • Corresponding patent litigation in Germany has been ongoing since June 2022.
  • The German litigation, which originated with a filing by CureVac regarding four of its intellectual property rights, now covers a fifth intellectual property right (EP 3 708 668 B1).